Unidentified Analyst: Okay. Great. Thanks for taking our questions. Much appreciated.
Tom Frinzi: Sure.
Operator: Thanks. Your next question comes from John Young from Canaccord. Your line is already open.
John Young: Hi, Tom, Patrick. Thanks for taking our questions. I just want to start on the US Highway 93. I’m curious about this program and maybe some of the comments that you made during the Q&A about being able to offset one practices offering the ones that near parity to LASIK. Are you discounting the lens as part of Route 93 or as a part of the co-marketing initiative? And how should we think about long-term AST specific to the United States? Thanks.
Tom Frinzi: Yes. Hey John, how are you? First of all, how’s your vision?
John Young: It’s great.
Tom Frinzi: Good. I always want to check in to make sure that EVO is performing as it should. But yes, specific to your question, as part of the alliance agreement and the volume commitment that a surgeon in that practice give us, there is some erosion of price, but it’s relatively within expectations. And I think, again, it cuts both ways right? We give a little bit on price. They give a little bit on what the consumer is paying and the combination thereof given our strong balance sheet and no debt and the cash we generate, we’re in a position to be a little bit more flexible to drive growth.
Patrick Williams: Yes. And remember, John, at the Investor Day, we outlined our Vision 2026. We provided a full P&L on the gross margin. I specifically addressed the fact that we would still stay at about 81% for all three years, which gives us a little bit of leeway wiggle room to be aggressive if we need to but more importantly to make sure, as Tom said, we’re giving a little there given a little. And so we did contemplate in our numbers currently and in our future numbers as well.
John Young: Okay. That’s great. Thank you. And then just for a follow-up too. The sales and marketing expense being down a lot quarter-over-quarter. I heard you talk about just pulling back on the digital ad. But is this part of the macro concerns to that you’ll be pulling back more here? And maybe you could just outline to when you came about the macro environment and I appreciate the information you gave in the United States about the overall procedure volumes continue to decline. In the past, you’ve talked about macro concerns being primarily in Europe. Do you think you’re going to see some impact now here in the United States too? Thanks again for taking the question.
Patrick Williams: Yes. Look, there’s a couple of things there. Certainly, in Europe, we’ve talked about the refractive markets being down. We are seeing it in the US. Tom outlined that in his call. We’re in mid-teens when you look at year-to-date. We’re starting to see that in even areas outside of China, which continues to grow but is down overall from a refractive, I would say, from this year compared to last year. With that said, we’re being very mindful about where we make our investments. We did have a step down in Q3. Some of that was timing which we pushed into Q4. But at this point, we’re not reducing I would say notably anything related to macro issues we’re seeing out there because we are still growing, as Tom outlined, during the call.
So as long as we’re seeing the growth, we’re seeing the good return will continue to grow. I think the big thing for us is as we get things in place where can we start putting more investment into areas in order to drive further adoption, whether it is in the US or certainly outside areas of the US.
Tom Frinzi: Patrick, I would only add John I think we’ve gotten smarter about how we’re investing and we’re going to invest dollars where we think they’re going to be rewarded the most. And that’s what’s happening.
John Young: Got it. Thanks. And then if I could sneak in one last one here. I may have missed the Patrick but did you reiterate the $18 million in US sales for this year for guidance?
